louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT05653011: Predictors of Prognosis in IBD Patients
Official title: Predictors of Response After Induction Therapy With TNF-alpha Inhibitor in Inflammatory Bowel Disease, Comparison to Normal
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Inflammatory Bowel Diseases
Ulcerative Colitis
Crohn Disease
Keywords: inflammatory bowel disease
ulcerative colitis
crohn's disease
Lead sponsor: Seoul National University Bundang Hospital
Sponsor class: OTHER
First posted: 2022-12-15
Enrollment: 100
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Observational model: CASE_CONTROL
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients who visited Seoul National University Bundang Hospital.

Brief summary: A study of clinical characteristics and potential prognostic factors in inflammatory bowel disease

Detailed description: Inflammatory bowel disease (IBD) is a chronic and relapsing inflammatory disease composed of two types: Crohn's disease (CD) and ulcerative colitis (UC). It is difficult to cure the IBD completely and patients with clinical or endoscopic remission can worsen again. Therefore, predicting the prognosis of patients with IBD is still challenging.

Endoscopic biopsied samples and blood samples from IBD patients and non-IBD controls have been collected and the expression levels of multiple markers which are associated with disease activity and severity will be assessed. The correlation between expression levels of multiple markers and prognosis will be evaluated.

Eligibility criteria: Inclusion Criteria:

* control group: Patients who do not have colitis, cancer, and advanced polyp (the number of polyps ≥ 3, the size of polyps ≥ 1cm, high-grade adenoma, villous adenoma)
* TNF-α inhibitor-naive IBD group: IBD patients who do not have a history of TNF-α inhibitor treatment
* TNF-α inhibitor-treated IBD group: IBD patients who are treated with TNF-α inhibitor

Exclusion Criteria:

* Age under 18 years
* Patients who were treated with antibiotics or probiotics within the last 3 months

Primary outcomes:
measure: The expression level of multiple markers associated with IBD activity or prognosis
timeFrame: baseline (at the time of enrollment)
Secondary outcomes:
measure: The change of expression level of multiple markers associated with IBD activity or prognosis
timeFrame: Every 2 years. The examination will be suspended when treatment was ended.
Other outcomes:
Locations:
city: Seongnam-si
country: Korea, Republic of
facility: Seoul National University Bundang Hospital
state: Gyeonggi-do
Study officials:
affiliation: Seoul National University Bundang Hospital
name: Nayoung Kim, M.D., Ph.D
role: STUDY_CHAIR
References:
Clinical trial NCT00112411: Comparison of Two Bronchodilator Inhalers in Pediatric Asthmatics
Official title: Dose-ranging Double-blind, Placebo-controlled Efficacy Comparison of Two Bronchodilator Inhalers in Pediatric Asthmatics
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Asthma
Lead sponsor: Teva Branded Pharmaceutical Products R&D, Inc.
Sponsor class: INDUSTRY
First posted: 2005-06-03
Sex: ALL
Minimum age (years): 4
Maximum age (years): 11
Standard ages: CHILD
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: TREATMENT

Brief summary: This study is designed to evaluate the single-dose effectiveness of two bronchodilator inhalers given at two dose levels in pediatric asthma patients.


Eligibility criteria: Inclusion Criteria:

* Persistent asthma for a minimum of six months duration that has been stable for at least four weeks
* Predicted FEV1 60-90%
* Demonstration of 12% airway reversibility

Exclusion Criteria:

* Continuous requirement for beta-blockers, monoamine oxidase (MAO) inhibitors, tricyclic antidepressants, anticholinergics and/or steroids other than those inhaled;
* Presence of clinically-significant non-asthmatic acute or chronic disease

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: San Diego
country: United States
facility: Allergy Associates Medical Group, Inc.
state: California
city: Savannah
country: United States
facility: Aeroallergy Research Labs of Savannah, Inc.
state: Georgia
city: Louisville
country: United States
facility: University of Louisville
state: Kentucky
city: North Dartmouth
country: United States
facility: Northeast Medical Research Associates, Inc.
state: Massachusetts
city: Jackson
country: United States
facility: Mississippi Asthma and Allergy Clinic
state: Mississippi
city: Raleigh
country: United States
facility: North Carolina Clinical Research
state: North Carolina
city: Eugene
country: United States
facility: Allergy and Asthma Research Group
state: Oregon
city: Portland
country: United States
facility: Allergy Associates Research Center
state: Oregon
city: The Woodlands
country: United States
facility: Medical Research Network
state: Texas
Study officials:
References:
Clinical trial NCT01906411: Dopaminergic Function and Food Reward
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Adiposity
Weight Loss
Lead sponsor: University Hospital Tuebingen
Sponsor class: OTHER
First posted: 2013-07-24
Enrollment: 36
Sex: FEMALE
Minimum age (years): 21
Maximum age (years): 45
Standard ages: ADULT
Accepts healthy volunteers: yes
Observational model: CASE_CROSSOVER
Time perspective: CROSS_SECTIONAL
Sampling method: NON_PROBABILITY_SAMPLE
Study population: community sample

Brief summary: The broad aim of the study is to obtain a better understanding of alterations in mesolimbic reward pathways in adiposity based on the hypothesis of a hypofunctioning reward system in obesity.

This will be achieved by integrating a functional neuroimaging (fMRI) with behavioral reward tasks and the modulation of the dopamine level by dopamine depletion.


Eligibility criteria: Inclusion Criteria:

* female
* healthy

Exclusion Criteria:

* fMRI contraindications
* claustrophobia

Primary outcomes:
measure: Differential brain functions in the dopaminergic reward system
timeFrame: 4 hours after intake of the dopamine depletion or balanced aminoacid drink
Secondary outcomes:
measure: amino acid level changes due to dopamine depletion
timeFrame: 4 hours after intake of the dopamine depletion or balanced aminoacid drink
Other outcomes:
Locations:
city: Tuebingen
country: Germany
facility: University Clinic of Tuebingen, MEG Center
Study officials:
References:
Clinical trial NCT04029311: Comparison of Two Techniques of Combination Therapy for Treatment of Obstructive Sleep Apnea (OSA)
Official title: Comparison of Two Techniques of Combination Therapy for Treatment of Obstructive Sleep Apnea (OSA)
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Treatment for Obstructive Sleep Apnea
Lead sponsor: Adame, J. Michael, D.D.S.
Sponsor class: INDIV
First posted: 2019-07-23
Enrollment: 28
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: To study the effects of two combination therapies for patients with obstructive sleep apnea (OSA) who have been both intolerant to Positive Airway Pressure (PAP) therapy and sub-therapeutic to oral appliance therapy.

Hypothesis

1. There is a difference between Continuous Positive Airway Pressure (CPAP) vs CPAP/Oral Appliance (OA) connect vs CPAP/OA disconnected in terms of:

1. Apnea Hypopnea Index (AHI) reduction
2. Amount of side effects
3. Amount of Leaks
4. Hours of use (compliance)
5. CPAP pressure

2. There is a difference between connected and disconnected for the following symptoms:

1. Epworth sleepiness Scale (ESS)
2. Functional Outcomes of Sleep Questionnaire (FOSQ)
3. Side effects Study Design - randomized prospective parallel


Eligibility criteria: Inclusion Criteria: Baseline diagnosis AHI \> or = 5 plus ESS . or = 10.

* PAP Intolerance
* Partial Response to oral appliance therapy: AHI \> 5
* Age: \> 18 Exclusion Criteria: History of daily use of alcohol, narcotics or Central Nervous System (CNS) depressants.
* Diagnosis of Central Sleep Apnea
* Pregnancy
* Edentulous
* Prisoners

Primary outcomes:
measure: Apnea-Hypopnea Index
timeFrame: 2 months
measure: PAP Pressure
timeFrame: 2 months
measure: Leaks
timeFrame: 2 months
measure: Hours of Use
timeFrame: 2 months
measure: Epworth Sleepiness Scale (ESS)
timeFrame: 2 months
measure: Functional Outcomes Sleep Questionnaire (FOSQ)
timeFrame: 2 months
measure: Intolerance Questionnaire
timeFrame: 2 months
Secondary outcomes:
Other outcomes:
Locations:
city: Edinburg
country: United States
facility: J. Michael Adame, DDS, PA
state: Texas
Study officials:
References:
Clinical trial NCT03258411: Evaluation Of Different Rapid Orthodontic Expansion Devices
Official title: Comparison of The Short Term Effects of Different Palatal Expanders Using CBCT.
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Cross Bite
Lead sponsor: King Abdulaziz University
Sponsor class: OTHER
First posted: 2017-08-23
Enrollment: 31
Sex: ALL
Minimum age (years): 10
Maximum age (years): 16
Standard ages: CHILD
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Evaluating and comparing the short term effects of different palatal expanders on the amount of palatal expansion and buccal tipping of posterior teeth.

Hypothesis:

H0: There is no difference in the short term effects between the different palatal expanders.

H1: There is a significant difference in the short term effects between the different palatal expanders.


Eligibility criteria: Inclusion Criteria:

* Non-syndromic adolescent patients.
* Patients in need for palatal expansion treatment.
* Average face height.
* No previous orthodontic treatment.

Exclusion Criteria:

* Syndromic adolescent patients.
* Patients not in need for palatal expansion treatment.
* Non-average face height.
* Previous orthodontic treatment.

Primary outcomes:
measure: Amount of skeletal and dental expansion
timeFrame: 3 months
measure: Amount of dental inclination
timeFrame: 3 months
Secondary outcomes:
Other outcomes:
Locations:
city: Jeddah
country: Saudi Arabia
facility: King Abdulaziz University, Faculty of Dentistry
state: Makkah
Study officials:
References:
citation: Mosleh MI, Kaddah MA, Abd ElSayed FA, ElSayed HS. Comparison of transverse changes during maxillary expansion with 4-point bone-borne and tooth-borne maxillary expanders. Am J Orthod Dentofacial Orthop. 2015 Oct;148(4):599-607. doi: 10.1016/j.ajodo.2015.04.040.
citation: Lagravere MO, Carey J, Heo G, Toogood RW, Major PW. Transverse, vertical, and anteroposterior changes from bone-anchored maxillary expansion vs traditional rapid maxillary expansion: a randomized clinical trial. Am J Orthod Dentofacial Orthop. 2010 Mar;137(3):304.e1-12; discussion 304-5. doi: 10.1016/j.ajodo.2009.09.016.
Clinical trial NCT05897411: Deconditioning of Acquired Food Aversion
Official title: Factors That Determine the Responses to Meal Ingestion: Deconditioning of Acquired Food Aversion
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Healthy
Keywords: meal ingestion
postprandial responses
hedonic sensations
homeostatic sensations
deconditioning
Lead sponsor: Hospital Universitari Vall d'Hebron Research Institute
Sponsor class: OTHER
First posted: 2023-06-09
Enrollment: 12
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: OTHER

Brief summary: Background. Aversive conditioning impairs the rewarding value of a comfort meal.

Our aim is to demonstrate the potential effect of deconditioning to reverse aversive conditioning and restore the hedonic postprandial response.

Methods: A sham-controlled, randomised, parallel, single-blind study will be performed on 12 healthy women (6 per group). The rewarding value of a comfort meal will be measured at initial exposure, after aversive conditioning (masked administration of the same meal with a high-fat content) and after a deconditioning intervention (unmasking the aversive conditioning paradigm in the deconditioning group vs sham intervention in the control group). Digestive well-being (primary outcome) will be measured every 10 min before and 60 min after ingestion using graded scales. The effect of deconditioning (change from aversive conditioning to deconditioning) will be compared to sham deconditioning in the control group.

Expected results: The comfort meal at first exposure will induce a pleasant postprandial experience, which will be impaired by aversive conditioning; this effect will be reverted by deconditioning and the hedonic value of the comfort meal will be restored.


Eligibility criteria: Inclusion Criteria:

-

Inclusion Criteria:

* non-obese

Exclusion Criteria:

* history of gastrointestinal symptoms
* prior obesity
* use of medications
* history of anosmia and ageusia
* current dieting
* alcohol abuse
* psychological disorders
* eating disorders

Primary outcomes:
measure: Difference in postprandial digestive well-being before and after deconditioning
timeFrame: 120 minutes
measure: Difference in postprandial fullness sensation before and after conditioning
timeFrame: 120 minutes
measure: Change in postprandial mood before and after conditioning
timeFrame: 120 minutes
measure: Change in postprandial hunger/satiety before and after conditioning
timeFrame: 120 minutes
measure: Change in postprandial discomfort before and after conditioning
timeFrame: 120 minutes
Secondary outcomes:
Other outcomes:
Locations:
city: Barcelona
country: Spain
facility: Hospital Vall d'Hebron
Study officials:
References:
citation: Nieto A, Livovsky DM, Azpiroz F. Conditioning by a Previous Experience Impairs the Rewarding Value of a Comfort Meal. Nutrients. 2023 May 9;15(10):2247. doi: 10.3390/nu15102247.
Clinical trial NCT05494411: Named Patient Program for Mitomycin for Pyelocalyceal Solution
Study type: EXPANDED_ACCESS
Overall status: AVAILABLE
Conditions: Urothelial Cancer of Renal Pelvis
Urothelial Carcinoma of the Renal Pelvis and Ureter
Urothelial Carcinoma Ureter
Urothelial Carcinoma Ureter Recurrent
Urothelial Carcinoma
Urothelial Carcinoma Recurrent
Keywords: Low-grade Upper Tract Urothelial Cancer
LG-UTUC
UGN-101
Mitomycin
Lead sponsor: UroGen Pharma Ltd.
Sponsor class: INDUSTRY
Collaborators: name: Tanner Pharma Group
First posted: 2022-08-10
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT

Brief summary: This program provides controlled, pre-approval access to JELMYTO in response to unsolicited requests by physicians, hospitals, pharmacies, distributors, ministries of health or other parties on behalf of specific, or named patients, in select countries where JELMYTO has not yet received a marketing authorization and in situations when patients have exhausted all available treatment options.


Eligibility criteria: Inclusion Criteria:

* Patients who are suitable to receive JELMYTO and for whom there is reasonable expectation that JELMYTO may provide clinical benefit based on the medical judgment of their prescribing physician.

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT04353011: Psychological Impact of Quarantine in Chronic Pain Patient During COVID-19 Outbreak
Official title: Psychological Impact of Quarantine in Chronic Pain Patient During COVID-19 Outbreak
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Sars-CoV2
Chronic Pain
Keywords: Psychological impact
COVID-19
Lead sponsor: University Hospital, Lille
Sponsor class: OTHER
First posted: 2020-04-20
Enrollment: 312
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: FAMILY_BASED
Time perspective: CROSS_SECTIONAL
Sampling method: NON_PROBABILITY_SAMPLE
Study population: RA patient will be interviewed par internet questionnaire (patient association / AFVD)

Brief summary: In the context of quarantine with COVID-19, we will study the experience and psychological impact of pain in adult patients living with chronic pain. We will evaluate the link between the question of physical and psychological confinement in the experience of pain in this particular situation


Eligibility criteria: Inclusion Criteria:

* Patient with chronic pain
* Patient in confinement
* Patient with sufficient understanding of the French language

Exclusion Criteria:

* Non adult patient
* patient without quarantine

Primary outcomes:
measure: Hospital Anxiety and Depression Scale questionnaire
timeFrame: 1 week from baseline on
Secondary outcomes:
measure: Quality of life (SF36)
timeFrame: 1 week from baseline on
measure: self-reported questionnaire for painful
timeFrame: 1 week from baseline on
measure: qualitive questionnaire
timeFrame: 1 week from baseline on
Other outcomes:
Locations:
city: Lille
country: France
facility: Hopital Roger Salengro, CHU Lille
Study officials:
affiliation: University Hospital, Lille
name: Anne BERA, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00167011: Patterns of Coronary Artery Anatomy in Children With Congenital Heart Disease by Computed Tomography
Official title: Patterns of Coronary Artery Anatomy in Children With Congenital Heart Disease by Computed Tomography
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Heart Diseases
Keywords: coronary artery
Lead sponsor: National Taiwan University Hospital
Sponsor class: OTHER
First posted: 2005-09-14
Enrollment: 200
Sex: ALL
Minimum age (years): 1
Maximum age (years): 18
Standard ages: CHILD
ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Primary purpose: DIAGNOSTIC

Brief summary: To test the ability of electron beam CT in evalting the coronary artery pattern in children with congenital heart disease.

Detailed description: To test the ability of electron beam CT in evalting the coronary artery pattern in children with congenital heart disease.

Eligibility criteria: Inclusion Criteria:

- TOF, DORV, TGA, CCT

Exclusion Criteria:

-

Primary outcomes:
measure: diagnostic accuracy
Secondary outcomes:
measure: sensitivity
measure: specificity
Other outcomes:
Locations:
city: Taipei
country: Taiwan
facility: National Taiwan University Hospital
Study officials:
affiliation: National Taiwan University Hospital
name: Shyh-Jye Chen, MD, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT04730011: Short and Intensive Treatment of Children and Adolescents With Obsessive-Compulsive Disorder
Official title: Short and Intensive Treatment of Children and Adolescents With Obsessive-Compulsive Disorder - A Study to Evaluate the Effectiveness of an Intensive Treatment Week: "A Future Without Constraint"
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: NA
Conditions: Obsessive-Compulsive Disorder
Lead sponsor: Psychiatric University Hospital, Zurich
Sponsor class: OTHER
First posted: 2021-01-29
Enrollment: 100
Sex: ALL
Minimum age (years): 8
Maximum age (years): 18
Standard ages: CHILD
ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: Obsessive-compulsive disorders are very damaging illnesses; they can already appear in childhood and adolescence and become extremely chronic. With an average prevalence from 1-3%, they are among the most common psychiatric disorders in children and adolescents. 40% of diagnosed children and young adults display persistent and increasingly chronic symptoms and O-C disorders are highly complex syndromes with broadly varying manifestations. They arise from obsessive thoughts (ideas/thoughts or impulses, often senseless or tortured, that impose themselves or intrude) and obsessive behavior (ritualized patterns that must be frequently repeated).


Eligibility criteria: Inclusion Criteria:

* Obsessive-Compulsive Disorder diagnosis
* Male and female patients from 8-18 years
* Good German language speaking skills
* IQ of at least 75
* At least four days' participation in the treatment/therapy week
* Written agreement after clear explanation

Exclusion Criteria:

- No complete participation in the intensive week treatment/therapy

Primary outcomes:
measure: Symptoms severity of obsessive and compulsive symptoms in children and adolescents
timeFrame: 12 months
Secondary outcomes:
Other outcomes:
Locations:
city: Zurich
country: Switzerland
facility: Psychiatric University Clinics, Department of Child and Adolescent Psychiatry
state: ZH
Study officials:
affiliation: Sponsor GmbH
name: Susanne Walitza, Prof. Dr. med. Dipl.-Psych.
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06885411: Ototoxicity in Patients With MoM Hip Bearings
Official title: Ototixicity in Patients With a Metal-on-Metal Hip Arthroplasty
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Ototoxic Hearing Loss
Cobalt Poisoning
Chromium Causing Toxic Effect
Arthroplasty Complications
Keywords: Metal-on-Metal implant; Cobalt; Chromium; Hip arthroplasty; auditory system; Otoxicity
Lead sponsor: Reinier Haga Orthopedisch Centrum
Sponsor class: OTHER
Collaborators: name: Reinier de Graaf Groep
name: Erasmus Medical Center
name: Zuyderland Medical Centre
First posted: 2025-03-20
Enrollment: 200
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: All patients in the participating hospitals with a MoM hip arthroplasty or a revised MoM hip arthroplasty.

Brief summary: The goal of this observational study is to learn about ototoxicity in patients with a MoM hip arthroplasty. The main question it aims to answer is:

• What is the prevalence of hearing loss in patients with high and low plasma metal concentrations.


Eligibility criteria: Inclusion Criteria:

* all MoM patients from the different clinics
* revision MoM
* willing to participate
* speak/write the Dutch language

Exclusion Criteria:

* Not willing to participate
* previous ENT surgery or ENT pathology

Primary outcomes:
measure: Mid frequency hearing loss
timeFrame: Participants will perform a hearing test once during the study, during a visit of the outpatient clinic.
Secondary outcomes:
measure: Age
timeFrame: Age will be determined once for each participant, at time of the visit of the outpatient clinic
measure: subjective general health and subjective hearing loss measured with the Amsterdam Inventory for Auditory Disability and Handicap questionnaire.
timeFrame: The questionnaire will be completed once by each participant, at time of the visit of the outpatient clinic
measure: BMI
timeFrame: Lenght and weight will be determined once for each participant, at time of the visit of the outpatient clinic
measure: Cobalt serum concentration
timeFrame: Cobalt serum concentration will be determined once for each participant, at time of the visit of the outpatient clinic
measure: Chromium serum concentration
timeFrame: Chromium serum concentration will be determined once for each participant, at time of the visit of the outpatient clinic
Other outcomes:
Locations:
city: Delft
country: Netherlands
facility: Reinier de Graaf Ziekenhuis
Study officials:
References: